United States Biotechnology & Medical Research

Galera Therapeutics Inc (GRTX)

Track

The most recent insider trading activity at Galera Therapeutics Inc. occurred on November 20, 2025, involving a sale of 70,000 shares by President and CEO Mel Sorensen. Prior to this, the company saw significant buying activity in late 2024. No insider transactions have been recorded within the last three months.
Ticker: GRTX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Galera Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.6
Sorensen Mel President and CEO Executive Director
Transaction date
Sale
Price
235.78
Quantity 3,343 +1.0%
Value US$464,447
2.6
Sorensen Mel Officer Officer
Transaction date
Proposed sale
Price
289.73
Quantity 816
Value US$4,580,759
CHANG NANCY T Non-Executive Director Large shareholder
Transaction date
Purchase
Price
358.69
Quantity 63,773 +36.8%
Value US$4,740,093
2.6
Sorensen Mel President and CEO Executive Director
Transaction date
Sale
Price
0.07
Quantity 67,015 -20.2%
Value US$4,825
2.6
Sorensen Mel Officer; Director Executive Director
Transaction date
Proposed sale
Price
0.07
Quantity 67,015
Value US$4,825
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.17
Quantity 150,000 +1.9%
Value US$25,650
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.17
Quantity 150,000 +1.9%
Value US$25,935
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.17
Quantity 25,000 +0.3%
Value US$4,250
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.20
Quantity 25,000 +0.3%
Value US$5,025
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.18
Quantity 97,402 +1.3%
Value US$17,922
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.18
Quantity 335,000 +4.6%
Value US$60,635
2.7
Schneid Yair Large shareholder
Transaction date
Purchase
Price
0.18
Quantity 150,000 +2.1%
Value US$27,000
3.2
Bachleda Mark Chief Commercial Officer Officer
Transaction date
Purchase
Price
2.25
Quantity 11,000 +inf%
Value US$24,717
2.2
Degnan Chris Chief Financial Officer Officer
Transaction date
Purchase
Price
1.96
Quantity 10,000 +inf%
Value US$19,593
2.6
Sorensen Mel President and CEO Executive Director
Transaction date
Purchase
Price
1.68
Quantity 100,000 +43.1%
Value US$168,120
2.7
West Linda Non-Executive Director
Transaction date
Purchase
Price
2.74
Quantity 20,000 +50.0%
Value US$54,804
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
8.47
Quantity 47,756 -100.0%
Value US$404,498
2.7
West Linda Non-Executive Director
Transaction date
Purchase
Price
9.13
Quantity 10,000 +33.3%
Value US$91,300
2.7
West Linda Non-Executive Director
Transaction date
Purchase
Price
8.65
Quantity 10,000 +50.0%
Value US$86,511
1.8
Alleva Lawrence M Non-Executive Director
Transaction date
Purchase
Price
8.59
Quantity 4,045 +inf%
Value US$34,741
2.7
West Linda Non-Executive Director
Transaction date
Purchase
Price
8.64
Quantity 10,000 +100.0%
Value US$86,381
2.7
West Linda Non-Executive Director
Transaction date
Purchase
Price
8.64
Quantity 10,000 +inf%
Value US$86,410
2.3
Novo Holdings A/S Large shareholder
Transaction date
Sale
Price
10.58
Quantity 500,000 -16.9%
Value US$5,290,000
1.8
Alleva Lawrence M Non-Executive Director
Transaction date
Purchase
Price
10.22
Quantity 2,325 +58.1%
Value US$23,771
1.1
Sussman Joel F. Chief Accounting Officer Officer
Transaction date
Sale
Price
10.32
Quantity 10,000 -100.0%
Value US$103,197
1.1
Sussman Joel F. Chief Accounting Officer Officer
Transaction date
Sale
Price
10.06
Quantity 10,000 -100.0%
Value US$100,627
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
15.00
Quantity 2,244 -100.0%
Value US$33,660
2.3
Novo Holdings A/S Large shareholder
Transaction date
Sale
Price
11.00
Quantity 450,000 -13.2%
Value US$4,950,000
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 10,536 -100.0%
Value US$126,432
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 100 -100.0%
Value US$1,200
2.7
Novartis Bioventures Ltd Former 10% Owner
Transaction date
Sale
Price
8.25
Quantity 1,001,312 -28.9%
Value US$8,260,824
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 692 -100.0%
Value US$8,304
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 1,174 -100.0%
Value US$14,088
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 969 -100.0%
Value US$11,628
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 671 -100.0%
Value US$8,052
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 185 -100.0%
Value US$2,220
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 5,102 -100.0%
Value US$61,224
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 2,059 -100.0%
Value US$24,709
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.00
Quantity 1,489 -100.0%
Value US$17,868
HOLMLUND JON T Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.16
Quantity 3,064 -100.0%
Value US$37,258
Alleva Lawrence M Non-Executive Director
Transaction date
Purchase
Price
9.78
Quantity 4,000 +inf%
Value US$39,139
1.5
Clarus IV-A, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 19,423 +17.5%
Value US$233,076
1.5
Clarus IV-A, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 97,131 +17.5%
Value US$1,165,572
1.5
Clarus IV-A, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 52,660 +17.5%
Value US$631,920
1.5
Clarus IV-A, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 80,786 +17.5%
Value US$969,432
2.3
Novo Holdings A/S SEE REMARKS Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 500,000 +17.2%
Value US$6,000,000
Sofinnova Venture Partners IX, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 750,000 +32.1%
Value US$9,000,000
New Enterprise Associates 14, L.P. Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 416,666 +10.6%
Value US$4,999,992
Novartis Bioventures Ltd Large shareholder
Transaction date
Purchase
Price
12.00
Quantity 250,000 +7.6%
Value US$3,000,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-24 2025-11-20 S Sale
2.6
Sorensen Mel

President and CEO

Executive Director
3,343 +1.0%
235.78
US$464,447 		3,343 +1.0% 235.78 US$464,447
2025-11-20 2025-11-20 PrS Proposed sale
2.6
Sorensen Mel

Officer

Officer
816
289.73
US$4,580,759 		816 289.73 US$4,580,759
2025-01-02 2024-12-30 B Purchase
CHANG NANCY T
Non-Executive Director Large shareholder
63,773 +36.8%
358.69
US$4,740,093 		63,773 +36.8% 358.69 US$4,740,093
2024-08-20 2024-08-16 S Sale
2.6
Sorensen Mel

President and CEO

Executive Director
67,015 -20.2%
0.07
US$4,825 		67,015 -20.2% 0.07 US$4,825
2024-08-16 2024-08-16 PrS Proposed sale
2.6
Sorensen Mel

Officer; Director

Executive Director
67,015
0.07
US$4,825 		67,015 0.07 US$4,825
2024-02-26 2024-02-08 B Purchase
2.7
Schneid Yair
Large shareholder
150,000 +1.9%
0.17
US$25,650 		150,000 +1.9% 0.17 US$25,650
2024-02-26 2024-02-07 B Purchase
2.7
Schneid Yair
Large shareholder
150,000 +1.9%
0.17
US$25,935 		150,000 +1.9% 0.17 US$25,935
2024-02-26 2024-02-07 B Purchase
2.7
Schneid Yair
Large shareholder
25,000 +0.3%
0.17
US$4,250 		25,000 +0.3% 0.17 US$4,250
2024-02-26 2024-02-06 B Purchase
2.7
Schneid Yair
Large shareholder
25,000 +0.3%
0.20
US$5,025 		25,000 +0.3% 0.20 US$5,025
2024-02-26 2024-02-05 B Purchase
2.7
Schneid Yair
Large shareholder
97,402 +1.3%
0.18
US$17,922 		97,402 +1.3% 0.18 US$17,922
2024-02-26 2024-01-30 B Purchase
2.7
Schneid Yair
Large shareholder
335,000 +4.6%
0.18
US$60,635 		335,000 +4.6% 0.18 US$60,635
2024-02-26 2024-01-29 B Purchase
2.7
Schneid Yair
Large shareholder
150,000 +2.1%
0.18
US$27,000 		150,000 +2.1% 0.18 US$27,000
2023-03-20 2023-03-16 B Purchase
3.2
Bachleda Mark

Chief Commercial Officer

Officer
11,000 +inf%
2.25
US$24,717 		11,000 +inf% 2.25 US$24,717
2023-03-14 2023-03-13 B Purchase
2.2
Degnan Chris

Chief Financial Officer

Officer
10,000 +inf%
1.96
US$19,593 		10,000 +inf% 1.96 US$19,593
2023-03-14 2023-03-10 B Purchase
2.6
Sorensen Mel

President and CEO

Executive Director
100,000 +43.1%
1.68
US$168,120 		100,000 +43.1% 1.68 US$168,120
2021-12-20 2021-12-17 B Purchase
2.7
West Linda
Non-Executive Director
20,000 +50.0%
2.74
US$54,804 		20,000 +50.0% 2.74 US$54,804
2021-09-03 2021-09-01 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
47,756 -100.0%
8.47
US$404,498 		47,756 -100.0% 8.47 US$404,498
2021-06-17 2021-06-15 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +33.3%
9.13
US$91,300 		10,000 +33.3% 9.13 US$91,300
2021-06-04 2021-06-02 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +50.0%
8.65
US$86,511 		10,000 +50.0% 8.65 US$86,511
2021-06-03 2021-06-01 B Purchase
1.8
Alleva Lawrence M
Non-Executive Director
4,045 +inf%
8.59
US$34,741 		4,045 +inf% 8.59 US$34,741
2021-06-02 2021-06-01 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +100.0%
8.64
US$86,381 		10,000 +100.0% 8.64 US$86,381
2021-06-02 2021-05-28 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +inf%
8.64
US$86,410 		10,000 +inf% 8.64 US$86,410
2021-02-19 2021-02-18 S Sale
2.3
Novo Holdings A/S
Large shareholder
500,000 -16.9%
10.58
US$5,290,000 		500,000 -16.9% 10.58 US$5,290,000
2020-11-17 2020-11-13 B Purchase
1.8
Alleva Lawrence M
Non-Executive Director
2,325 +58.1%
10.22
US$23,771 		2,325 +58.1% 10.22 US$23,771
2020-11-16 2020-11-13 S Sale
1.1
Sussman Joel F.

Chief Accounting Officer

Officer
10,000 -100.0%
10.32
US$103,197 		10,000 -100.0% 10.32 US$103,197
2020-11-16 2020-11-12 S Sale
1.1
Sussman Joel F.

Chief Accounting Officer

Officer
10,000 -100.0%
10.06
US$100,627 		10,000 -100.0% 10.06 US$100,627
2020-10-28 2020-10-26 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
2,244 -100.0%
15.00
US$33,660 		2,244 -100.0% 15.00 US$33,660
2020-10-19 2020-10-15 S Sale
2.3
Novo Holdings A/S
Large shareholder
450,000 -13.2%
11.00
US$4,950,000 		450,000 -13.2% 11.00 US$4,950,000
2020-10-07 2020-10-06 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
10,536 -100.0%
12.00
US$126,432 		10,536 -100.0% 12.00 US$126,432
2020-10-07 2020-10-05 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
100 -100.0%
12.00
US$1,200 		100 -100.0% 12.00 US$1,200
2020-06-22 2020-06-19 S Sale
2.7
Novartis Bioventures Ltd

Former 10% Owner
1,001,312 -28.9%
8.25
US$8,260,824 		1,001,312 -28.9% 8.25 US$8,260,824
2020-06-22 2020-06-18 S Sale
2.7
Novartis Bioventures Ltd

Former 10% Owner
900 -0.0%
9.04
US$8,136 		900 -0.0% 9.04 US$8,136
2020-06-17 2020-06-17 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
4,622 -0.1%
9.27
US$42,846 		4,622 -0.1% 9.27 US$42,846
2020-06-17 2020-06-16 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
8,600 -0.2%
9.30
US$79,980 		8,600 -0.2% 9.30 US$79,980
2020-06-17 2020-06-15 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
6,164 -0.2%
9.05
US$55,784 		6,164 -0.2% 9.05 US$55,784
2020-06-12 2020-06-12 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
1,500 -0.0%
9.19
US$13,785 		1,500 -0.0% 9.19 US$13,785
2020-06-12 2020-06-11 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
7,200 -0.2%
9.21
US$66,312 		7,200 -0.2% 9.21 US$66,312
2020-06-12 2020-06-10 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
8,532 -0.2%
9.46
US$80,713 		8,532 -0.2% 9.46 US$80,713
2020-06-09 2020-06-09 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
7,000 -0.2%
9.38
US$65,660 		7,000 -0.2% 9.38 US$65,660
2020-06-09 2020-06-08 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
5,659 -0.2%
9.66
US$54,666 		5,659 -0.2% 9.66 US$54,666
2020-06-09 2020-06-05 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
8,652 -0.2%
9.66
US$83,578 		8,652 -0.2% 9.66 US$83,578
2020-06-04 2020-06-04 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
4,088 -0.1%
9.55
US$39,040 		4,088 -0.1% 9.55 US$39,040
2020-06-04 2020-06-03 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
5,208 -0.1%
9.78
US$50,934 		5,208 -0.1% 9.78 US$50,934
2020-06-04 2020-06-02 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
5,669 -0.2%
9.68
US$54,876 		5,669 -0.2% 9.68 US$54,876
2020-05-28 2020-05-26 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
692 -100.0%
12.00
US$8,304 		692 -100.0% 12.00 US$8,304
2020-05-22 2020-05-21 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
1,174 -100.0%
12.00
US$14,088 		1,174 -100.0% 12.00 US$14,088
2020-05-22 2020-05-20 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
969 -100.0%
12.00
US$11,628 		969 -100.0% 12.00 US$11,628
2020-05-12 2020-05-12 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
671 -100.0%
12.00
US$8,052 		671 -100.0% 12.00 US$8,052
2020-05-12 2020-05-11 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
185 -100.0%
12.00
US$2,220 		185 -100.0% 12.00 US$2,220
2020-05-12 2020-05-08 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
5,102 -100.0%
12.00
US$61,224 		5,102 -100.0% 12.00 US$61,224
2020-05-07 2020-05-07 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
2,059 -100.0%
12.00
US$24,709 		2,059 -100.0% 12.00 US$24,709
2020-05-07 2020-05-06 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
1,489 -100.0%
12.00
US$17,868 		1,489 -100.0% 12.00 US$17,868
2020-05-07 2020-05-05 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
3,064 -100.0%
12.16
US$37,258 		3,064 -100.0% 12.16 US$37,258
2019-12-17 2019-12-13 B Purchase Alleva Lawrence M Non-Executive Director
4,000 +inf%
9.78
US$39,139 		4,000 +inf% 9.78 US$39,139
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
19,423 +17.5%
12.00
US$233,076 		19,423 +17.5% 12.00 US$233,076
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
97,131 +17.5%
12.00
US$1,165,572 		97,131 +17.5% 12.00 US$1,165,572
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
52,660 +17.5%
12.00
US$631,920 		52,660 +17.5% 12.00 US$631,920
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
80,786 +17.5%
12.00
US$969,432 		80,786 +17.5% 12.00 US$969,432
2019-11-14 2019-11-12 B Purchase
2.3
Novo Holdings A/S

SEE REMARKS

Large shareholder
500,000 +17.2%
12.00
US$6,000,000 		500,000 +17.2% 12.00 US$6,000,000
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
19,423 +17.5%
12.00
US$233,076 		19,423 +17.5% 12.00 US$233,076
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
97,131 +17.5%
12.00
US$1,165,572 		97,131 +17.5% 12.00 US$1,165,572
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
52,660 +17.5%
12.00
US$631,920 		52,660 +17.5% 12.00 US$631,920
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
80,786 +17.5%
12.00
US$969,432 		80,786 +17.5% 12.00 US$969,432
2019-11-12 2019-11-12 B Purchase Sofinnova Venture Partners IX, L.P. Large shareholder
750,000 +32.1%
12.00
US$9,000,000 		750,000 +32.1% 12.00 US$9,000,000
2019-11-12 2019-11-12 B Purchase New Enterprise Associates 14, L.P. Large shareholder
416,666 +10.6%
12.00
US$4,999,992 		416,666 +10.6% 12.00 US$4,999,992
2019-11-12 2019-11-12 B Purchase Novartis Bioventures Ltd Large shareholder
250,000 +7.6%
12.00
US$3,000,000 		250,000 +7.6% 12.00 US$3,000,000
Explore more

More insider trading research around Galera Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America